Clovis' Perfect Story Gets Shredded
By Max Nisen
Nov 16, 2015
The response rate plunged from 67 percent to 28 percent for a smaller dose and 35 percent for a larger one. AstraZeneca's direct competitor Tagrisso, approved just last week, has a confirmed response rate about double that.
In other words, rocilitenib is, as Bloomberg Intelligence analyst Asthika Goonewardene puts it, "toast."
Do the homework
Great Entry For Near Term Earnings.
thanxs for the shares
Japan shares look to snap six-day losing streak
Japan's benchmark stock-market index pushed higher on Wednesday as traders there got a chance to react to China's rate cut.